Drug Discovery World

MAY 2, 2024

Hailed as a revolution in the treatment of many diseases, cell and gene therapy (CGT) is the fastest growing area of therapeutics. Perhaps most significantly, Casgevy (or exa-cel) from Vertex Pharmaceuticals and CRISPR Therapeutics, was approved to treat sickle cell disease and became the first gene therapy that uses CRISPR gene editing.

Therapies 148

Therapies FDA Clinical Research Marketing 148

Drug Discovery World

JULY 22, 2024

Keir Loiacono , CEO of BlueSphere Bio, discusses the goals of the company’s lead programme, the opportunities and potential of T-cell receptor (TCR) T cell therapies, and how to make oncology therapies tailored to individuals a reality. The goals of TCX-101 BlueSphere’s lead programme, TCX-101, includes two goals.

Therapies 130

Therapies Engineering Treatment Pharma Companies 130

Drug Discovery World

FEBRUARY 21, 2024

DDW Editor Reece Armstrong speaks to Dr Paul Song , MD, NKGen and Dr Vince DeOrchis , clinician, to find out more about the investigational natural killer therapy SNK01 and the benefit of using a patient’s own cells to treat Alzheimer’s. PS : Most, if not all, current therapies are focused on MCI. RA: How does SNK01 work?

Therapies 307

Therapies Trials Treatment Disease 307

Drug Discovery World

JULY 30, 2024

Tecvayli (teclistamab) has been recommended for relapsed and refractory multiple myeloma (RRMM) in England and Wales, leading analysts to predict Johnson & Johnson (J&J) will dominate the bispecific T-cell engagers (BiTEs) market by 2030. Talvey is estimated to become the second top-selling BiTE, with $2 billion.

Marketing 130

Marketing Treatment Therapies Production 130

Drug Discovery World

APRIL 8, 2024

Dr Nigam will outline the role of software in accelerating the pace of discovery of antibody therapeutics while Dr Genevini will discuss the generation of recombinant tool antibodies to support cell and gene therapy development. What you will learn: Where is the opportunity in the mAb market and where is the market heading?

Marketing 148

Marketing Engineering Therapies Research 148

Drug Discovery World

APRIL 15, 2024

Join DDW for this free event ‘ Where is the opportunity in the therapeutic antibody market? ’, which is co-sponsored by Bio-Rad and Benchling. Dr Paola Genevini will discuss the generation of recombinant tool antibodies to support cell and gene therapy development. Register for free now to secure your place.

Marketing 130

Marketing Engineering Therapies Disease 130

Drug Discovery World

JUNE 1, 2023

A Nature publication confirmed that there are currently 12 FDA-approved ADCs on the market, and nine of these secured FDA approval in the past six years 2. DDW’s Megan Thomas explores three trends in the market. Varying sources suggest that China has been one to watch over recent years and continues to be going forward.

Marketing 245

Marketing FDA Approval Licensing Licensing 245

Drug Discovery World

APRIL 8, 2024

Join DDW for this free event ‘ Where is the opportunity in the therapeutic antibody market? ’, which is co-sponsored by Bio-Rad and Benchling. Dr Paola Genevini will discuss the generation of recombinant tool antibodies to support cell and gene therapy development. The post Where is the opportunity in the therapeutic antibody market?

Marketing 130

Marketing Engineering Therapies Disease 130

Drug Discovery World

MAY 7, 2024

Dr Nigam will outline the role of software in accelerating the pace of discovery of antibody therapeutics while Dr Genevini will discuss the generation of recombinant tool antibodies to support cell and gene therapy development. What you will learn: Where is the opportunity in the mAb market and where is the market heading?

Marketing 130

Marketing Engineering Therapies Drugs 130

Drug Discovery World

JUNE 23, 2023

Sarepta Therapeutics’ Elevidys has become the first gene therapy for Duchenne muscular dystrophy (DMD) to gain marketing authorisation in the US. The accelerated approval follows a vote of support from the FDA Cellular, Tissue and Gene Therapies Advisory Committee and the granting of priority review status.

FDA Approval 243

FDA Approval Therapies FDA Protein Expression 243

Drug Discovery World

MAY 20, 2024

Glucagon-like peptide-1 (GLP-1) receptor agonist sales for the type 2 diabetes and obesity markets are forecast to reach over $125 billion in the seven major markets (7MM) by 2033, according to analysts GlobalData. But there is an opportunity for new players to join the race, as the market is vast.

Marketing 130

Marketing Doctors Clinical Development Therapies 130

Drug Discovery World

APRIL 29, 2024

Join DDW for this free event ‘ Where is the opportunity in the therapeutic antibody market? ’, which is co-sponsored by Bio-Rad and Benchling. Dr Paola Genevini will discuss the generation of recombinant tool antibodies to support cell and gene therapy development. Register for free now to secure your place.

Marketing 130

Marketing Engineering Therapies Disease 130

Drug Discovery World

JANUARY 30, 2024

Viral vector manufacturing At the Advanced Therapies Awards ceremony, Dr Luigi Naldini, Director of the San Raffaele Telethon Institute for Gene Therapy, was awarded a Lifetime Achievement Award in recognition of ‘extraordinary contributions to gene therapy’, a field he has helped shape through his pioneering work on lentiviral vectors.

Therapies 180

Therapies Clinical Trials Trials Production 180

Drug Discovery World

JULY 12, 2024

AB-1005 is an investigational adeno-associated virus 2 glial cell line-derived neurotrophic factor (AAV2-GDNF) neurorestorative gene therapy. The UK MHRA Innovation Passport is the entry point to the Innovative Licensing and Access Pathway (ILAP), which aims to accelerate time to market, facilitating patient access.

Therapies 148

Therapies Clinical Trials FDA Clinical Development 148

Drug Discovery World

APRIL 30, 2024

Download this In Focus eReport to gain a full understanding of the current market for CGTs and the areas of greatest commercial potential for the future.

Therapies 130

Therapies Marketing Drugs 130

Drug Discovery World

JUNE 11, 2024

The European Medicines Agency has approved a Type II variation to the Summary of Product Characteristics (SmPC) for Kite’s chimeric antigen receptor (CAR)-T cell therapies, Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel).

Therapies 130

Therapies Clinical Trials Hospitals International 130

Drug Discovery World

NOVEMBER 22, 2023

The European Commission (EC) has granted marketing authorisation for YORVIPATH (palopegteriparatide) as replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism. YORVIPATH is Ascendis Pharma’s prodrug of parathyroid hormone (PTH 1-34), administered once daily.

Marketing 130

Marketing Drugs Therapies Regulations 130

Drug Discovery World

AUGUST 14, 2023

Lung-I Cheng, Vice President and Head of Cell & Gene Therapy Service Line at AmerisourceBergen, and Cori Gorman, Senior Director of CMC and Regulatory Affairs at Biopharma Excellence, offer advice on navigating the different and sometimes contradictory regulatory requirements in the US and EU. billion in 2020 to $15.5

Marketing 130

Marketing DNA Therapies FDA 130

Drug Discovery World

FEBRUARY 22, 2024

market capitalisation growth to $3.67 The top 20 global biopharmaceutical companies experienced varied year-on-year (YoY) market capitalisation shifts in 2023 amid the macroeconomic headwinds, steep patent cliffs and the commencement of US drug price negotiations under the Inflation Reduction Act (IRA).

Marketing 130

Marketing FDA Approval Biosimilars FDA 130

Drug Discovery World

JANUARY 31, 2024

Mark Treherne will talk about advanced therapies and the development of RNA gene therapy for aggressive cancers which is being carried out at Spliceor. Doug Danison will discuss transitioning innovative science into commercial success in the areas of CGTs.

Therapies 130

Therapies RNA Science Marketing 130

Drug Discovery World

OCTOBER 4, 2023

Findings from the RESMAIN study of 4SC’s resminostat (Kinselby) treatment show that the therapy can postpone disease progression in advanced CTCL. Maintenance therapies are used to prolong the period patients are stable and where their disease is not progressing. months, compared to 14.9 months for those in the placebo group.

Marketing 130

Marketing Treatment Therapies Disease 130

Drug Discovery World

NOVEMBER 27, 2023

This 24-page eBook sponsored by Sartorius explores the latest innovations in cell and gene therapies, where the challenges lie and the possible solutions to overcoming these obstacles.

Therapies 130

Therapies Disease Marketing Drugs 130

Drug Discovery World

AUGUST 4, 2023

Dr Christian K Schneider , Head of Biopharma Excellence at PharmaLex, presents the findings of an industry panel debate on barriers to commercialisation of novel treatments, and the most effective strategies to bring them to market. Other challenges involve talent gaps, particularly now that cell and gene therapy manufacturing is maturing.

Therapies 130

Therapies Pharma Companies Treatment Marketing 130

Drug Discovery World

FEBRUARY 15, 2024

Mark Treherne will talk about advanced therapies and the development of RNA gene therapy for aggressive cancers which is being carried out at Spliceor.

Therapies 130

Therapies RNA Science Marketing 130

Drug Discovery World

FEBRUARY 22, 2024

Mark Treherne will talk about advanced therapies and the development of RNA gene therapy for aggressive cancers which is being carried out at Spliceor. Doug Danison will discuss transitioning innovative science into commercial success in the areas of CGTs.

Therapies 130

Therapies RNA Science Marketing 130

Drug Discovery World

AUGUST 30, 2022

The Phacilitate Advanced Therapies Europe 2022 conference will take place from 30 August to 1 September at the Royal Lancaster in London, UK. The conference is the European twin to Phacilitate Advanced Therapies Week, an event held in January in Florida, US. Creating a sustainable cell & gene therapy company.

Therapies 246

Therapies Hospitals Clinical Trials Clinical Development 246

Drug Discovery World

OCTOBER 18, 2023

Sara Donnelly, Director of Research Planning and Business Development at PhoenixBio USA explores why the right pre-clinical model is essential for teams wanting to advance adeno-associated virus vector-based gene therapies. Adeno-associated virus (AAV) vector-based gene therapies hold exceptional promise across a range of disease areas.

Therapies 163

Therapies Clinical Trials FDA Approval Virus 163

Drug Discovery World

NOVEMBER 24, 2022

DDW’s Diana Spencer asks what will be needed for Europe to compete in the growing global market for advanced therapies. . In terms of ATMPs, other countries are ramping up support for these innovative therapies. China has meanwhile grown its share from 1% to 8%. . Boosting digital capabilities.

Therapies 245

Therapies Clinical Trials Pharmaceuticals Government 245

Fierce BioTech

MAY 19, 2023

Commercializing Gene Therapies, Part 4 – Market Entry This paper outlines three basic market archetypes for gene therapies and the key considerations leaders must address when prioritizing new potential markets.

Marketing 52

Marketing Therapies Science Research 52

Drug Discovery World

FEBRUARY 8, 2024

In 2023, DDW hosted a webinar, ‘A comprehensive guide to using adeno-associated virus (AAV) vectors in gene therapy’, supported by Azenta Life Sciences. AAV is optimal for gene therapy due to its efficiency and safety in humans; however, AAV processes can present obstacles for researchers. How is the titer determined?

Therapies 148

Therapies Bioinformatics Packaging Molecular Biology 148

Drug Discovery World

NOVEMBER 27, 2023

Hailed as a revolution in the treatment of many diseases, cell and gene therapy is the fastest growing area of therapeutics. The post New eBook: The latest innovations in cell and gene therapy appeared first on Drug Discovery World (DDW).

Therapies 130

Therapies Treatment Disease Marketing 130

Drug Discovery World

MAY 16, 2023

What are the global innovations in cell and gene therapy? What opportunities and challenges are emerging and can therapies get to market faster? Curbishley explains that as the wave of new therapies in development continues to increase, global pressures on manufacturing availability will become more acute.

Therapies 130

Therapies Clinical Trials Marketing Production 130

Drug Discovery World

MAY 5, 2023

The US market for medicines grew by 5% in 2022, reaching a total value of $429Bn on a net price basis. This was driven by a range of factors, including an increase in health services utilisation, which is now back to pre-pandemic levels, and the entry of new medicines into the market.

Marketing 130

Marketing Biosimilars Drugs Science 130

Drug Discovery World

FEBRUARY 21, 2024

Dr Mark Payton, CEO of Mercia, said: “The broader CGT market is a rapidly growing multi-billion-dollar market and its next stage of evolution is to focus down on technologies that reduce the cost of production and purification to ensure this therapeutic benefit is available for the many.

Therapies 130

Therapies Synthetic Chemistry Production Marketing 130

Drug Discovery World

JULY 11, 2022

Biotechnology company Awakn Life Sciences has received funding from Innovate UK to help it advance its ketamine-assisted therapy programme to market in the UK and US. . Awakn Life Sciences has developed a ketamine-assisted therapy programme for treating alcohol use disorder (AUD). The addiction treatment market?opportunity

Science 246

Science Therapies Clinical Trials Trials 246

Drug Discovery World

DECEMBER 8, 2023

Andrew Busey , Co-Founder, Form Bio discusses why vertical AI is set to reshape the cell and gene therapy sector. The cell and gene therapy industry is no exception to this digital transformation. It is imperative for the industry to communicate the precise composition and attributes of these therapies to regulatory bodies.

Therapies 163

Therapies Clinical Trials Small Molecule Production 163

Drug Discovery World

MARCH 25, 2024

Cardior is focused on the discovery and development of therapies that target RNA to prevent, repair and reverse diseases of the heart. We have been impressed by the scientific work carried out by the Cardior team, especially on CDR132L, which has a distinctive mode of action and potential to become a first-in-class therapy.”

Therapies 130

Therapies RNA Disease Trials 130